Related Experiment Video
Updated: Apr 29, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell
Adam J Olszewski1, Eric S Winer2, Jorge J Castillo3
1The Cancer Center, Memorial Hospital of Rhode Island, 111 Brewster Street, Pawtucket, RI 02860, United States.
Abstract:
Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, we investigated the relative benefits of adding rituximab to CHOP chemotherapy in diffuse large B-cell lymphoma (DLBCL) of extranodal origin, and found similar advantage for nodal and extranodal lymphomas. Hazard ratio for overall survival was 0.64 for nodal, and 0.70 for extranodal DLBCL. Hazard ratios for lymphoma-related death were 0.62 and 0.57, respectively. The advantage was largest for DLBCL of the spleen, liver and lung. Conversely, it was not evident for thyroid or testicular lymphomas. Compared with nodal DLBCL, spleen was the only site with significantly better prognosis after R-CHOP.
More Related Videos
Related Concept Videos
Treatment Resistant Cancers
Tumor Immunotherapy

